STRING OF PEARLS

TregTherapeutics’ technology platform is transformative in the truest sense of the word.

There is a well-known analogy, called a “String of Pearls,” that has gained recognition within the biotech/pharma industry. It was initially introduced by a respected leader in the industry to signify a strategic management concept of focusing upon an enterprise’s clearly defined areas of therapeutic strength and then strategically deciding upon which acquisition opportunities to pursue within those confines. We use the term to describe our technology platform – a coherent “string” upon which a series of curative vaccines, or “pearls,” are connected. Each pearl is strikingly similar, but at the same time, uniquely applicable to its own therapeutic indication within the scope of inflammatory autoimmune and neurodegenerative disease.

The TregTherapeutics technology platform is truly transformative in its simplicity, its elegance, and its universal application. The platform is based on an underlying mechanism of action that is a common denominator among all inflammatory diseases. The premise is that, built upon this platform, unique tolerogenic vaccines for specific diseases can be designed to eliminate the pathological immune response associated with them and to restore homeostasis. …Healing and restoration. Furthermore, this can be accomplished without global immunological compromise. TregTherapeutics is, thus, a purveyor of pearls, each a cure for a particular disease, strung upon the commonality of the science – a thing of beauty and a foundation for the dream that will free so many people from the scourge of chronic inflammatory disease. Yes, this is transformative, holding forth the promise of changing the world for millions of patients suffering from these devastating diseases.

We started with multiple sclerosis, have progressed into celiac disease, and further afield still with ALS. All in a coordinated strategy to move these vital therapeutic resources into clinical reality. Profound implications, pearl by pearl. .

This technology platform contains the secret for accomplishing so much for mankind. Elegant design and function linked together in a string of pearls that will change the world. A simple concept – a simple vaccine – a worthwhile enterprise – orchestrating human response to disease.

EXECUTIVE SUMMARY

The TregTherapeutics vaccine was developed by Dr. Mark Mannie of the Brody School of Medicine, East Carolina University, in Greenville, NC. Dr. Mannie’s 20 years of research have confirmed a unique approach to tolerogenic vaccines that has resulted in curing MS (EAE) in animal models. More than $6.0 million in cumulative NIH and NMSS grant funding has been invested in this tolerogenic vaccine platform. The Company holds an exclusive international license to this technology, and its mission is to orchestrate a transition from laboratory discoveries in animals to curative therapies for human patients around the world. As stated, the Company is seeking to establish partnerships to assist in broader application of the technology across autoimmune and neurodegenerative diseases.

Our core objective, multiple sclerosis, affects over 2.5 million people worldwide and the total worldwide market is estimated to exceed $19 billion. In addition to MS, the Company is currently embarked is specific development projects relating to celiac disease and ALS, these representative of neurodegenerative diseases including Alzheimer’s, Parkinson’s, Huntington’s as well as, autoimmune disease class that includes rheumatoid arthritis, diabetes, and dozens more.

The intention of management is to transition along well-defined preclinical paths and into Phase I and Phase IIa clinical trials within the next 18-24 months with celiac disease and with ALS. Rationale for these can be elaborated upon request. The current focus of attention is study design, communication with regulatory authorities, and compliance with remaining requirements for testing of the humanized vaccines. During the latter phases of clinical trial, it is the intention to partner with a pharmaceutical company that possesses the resources to move the therapy through the latter stages of regulatory activity. There are several exit points that may accelerate development and expedite market entry.

Series A funding is being sought that will be sufficient for the company to support corporate operations and execute development objectives. Term sheet is available upon request.

Learn More

Would you like to take part in changing the world?
May we explain how?

CONTACT US